Abstracts tagged "Interleukins"

Abstract Number: 0240 • ACR Convergence 2020
Long-term Safety and Efficacy of Sarilumab over 5 Years in Patients with Rheumatoid Arthritis with 1 or >1 Prior Tumor Necrosis Factor Inhibitor Failures
Roy Fleischmann¹, Karina Maslova², Henry Leher³, Amy Praestgaard² and Gerd Burmester⁴, ¹Southwestern Medical Center, Metroplex Clinical Research Center, Dallas, TX, ²Sanofi, Cambridge, MA, ³Regeneron Pharmaceuticals, Inc, Tarrytown, NY, ⁴Charité University Hospital Berlin, Berlin, Germany
Background/Purpose: A proportion of adult patients with RA are refractory to TNF inhibitors (TNFi), and treatment with subsequent biologics may be associated with reduced response.…
Abstract Number: 0892 • ACR Convergence 2020
Long-Term Safety Profile of Ixekizumab Treatment in Patients with Axial Spondyloarthritis
Sergio Schwartzman¹, David Sandoval², Andris Kronbergs², Jeffrey Lisse³, Himanshu Patel³, Wen Xu³, Soyi Liu-Leage³, Marina Magrey⁴, Helena Marzo-Ortega⁵ and Denis Poddubnyy⁶, ¹Weill Cornell Medical College, New York, NY, ²Eli Lilly and Company, Indianapolis, ³Eli Lilly and Company, Indianapolis, IN, ⁴Case Western Reserve University School of Medicine, Cleveland, OH, ⁵The University of Leeds, Leeds Institute for Rheumatic and Musculoskeletal Medicine, NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust, Leeds, UK, Leeds, United Kingdom, ⁶Charité – Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: Ixekizumab, a high-affinity monoclonal antibody that selectively targets interleukin-17A, has demonstrated efficacy in the treatment of the axial spondyloarthritis (axSpA) spectrum (ankylosing spondylitis and…
Abstract Number: 1352 • ACR Convergence 2020
Bimekizumab Maintenance of Response in Patients with Psoriatic Arthritis: 2-Year Results from a Phase 2b Dose-Ranging Study and Its Open-Label Extension
Joseph Merola¹, Frank Behrens², Alan Kivitz³, Philip Mease⁴, Iain McInnes⁵, Barbara Ink⁶, Deepak Assudani⁷, Paulatsya Joshi⁷, Jason Coarse⁸ and Christopher Ritchlin⁹, ¹Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ²CIRI/Rheumatology & Fraunhofer IME, Research Division Translational Medicine and Pharmacology, Goethe University Hospital, Frankfurt, Hessen, Germany, ³Altoona Center for Clinical Research/Altoona Arthritis and Osteoporosis Center, Duncansville, PA, ⁴Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ⁵Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom, ⁶UCB Pharma, Slough, ⁷UCB Pharma, Slough, United Kingdom, ⁸UCB Pharma, Raleigh, NC, ⁹Department of Medicine, University of Rochester Medical Center, Rochester, NY
Background/Purpose: Bimekizumab (BKZ), a humanized monoclonal IgG1 antibody that selectively neutralizes interleukin (IL)-17A and IL-17F, has shown clinical improvements in joint and skin outcomes over…
Abstract Number: 0353 • ACR Convergence 2020
Achievement of Sustained Remission and Low Disease Activity with Secukinumab Improves Quality of Life and Physical Function in Patients with Psoriatic Arthritis: Results from a Randomized Phase 3 Study
Laura Coates¹, Philip Mease², Dafna Gladman³, Sandra Navarra⁴, Weibin Bao⁵ and Corine Gaillez⁶, ¹University of Oxford, Oxford, United Kingdom, ²Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ³Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ⁴University of Santo Tomas, Manila, Philippines, ⁵Novartis Pharmaceuticals Corporation, East Hannover, ⁶Novartis Pharma AG, Basel, Switzerland
Background/Purpose: A treat-to-target approach in psoriatic arthritis (PsA) was recommended by EULAR and GRAPPA to achieve remission (REM) or low disease activity (LDA), by regular…
Abstract Number: 0906 • ACR Convergence 2020
Bimekizumab Treatment Is Associated with Improvements in Back Pain and Fatigue in Patients with Active Psoriatic Arthritis: 48-Week Results from a Phase 2b Study
Atul Deodhar¹, Laure Gossec², Philip Mease³, Jason Coarse⁴, Heather Edens⁵, Natasha de Peyrecave⁶, Deepak Assudani⁶, Barbara Ink⁷ and Christopher Ritchlin⁸, ¹Oregon Health & Science University, Portland, OR, ²Sorbonne Université and Hôpital Universitaire Pitié Salpêtrière, Paris, France, ³Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ⁴UCB Pharma, Raleigh, NC, ⁵UCB Pharma, Smyrna, GA, ⁶UCB Pharma, Slough, United Kingdom, ⁷UCB Pharma, Slough, ⁸Department of Medicine, University of Rochester Medical Center, Rochester, NY
Background/Purpose: Patients (pts) with psoriatic arthritis (PsA) require effective treatment across all symptoms. Bimekizumab (BKZ) is a humanized IgG1 monoclonal antibody which selectively neutralizes interleukin…
Abstract Number: 1364 • ACR Convergence 2020
Bimekizumab Long-Term Efficacy and Safety over 96 Weeks in Patients with Ankylosing Spondylitis: Interim Results from a Phase 2b Open-Label Extension Study
Xenofon Baraliakos¹, Atul Deodhar², Maxime Dougados³, Marga Oortgiesen⁴, Natasha de Peyrecave⁵, Martin Bauer⁶, Thomas Vaux⁵, Carmen Fleurinck⁷ and Désirée van der Heijde⁸, ¹Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany, ²Oregon Health & Science University, Portland, OR, ³Université de Paris, Department of Rheumatology, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Paris, France, ⁴UCB Pharma, Raleigh, NC, ⁵UCB Pharma, Slough, United Kingdom, ⁶UCB Pharma, Monheim am Rhein, Germany, ⁷UCB Pharma, Brussels, Belgium, ⁸Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Bimekizumab (BKZ), a monoclonal antibody that selectively inhibits interleukin (IL)-17A and IL-17F, has demonstrated clinical efficacy in patients with ankylosing spondylitis (AS) treated over…
Abstract Number: 0356 • ACR Convergence 2020
Bimekizumab Improves Patient-Reported Outcomes in Psoriatic Arthritis: 48-Week Results from a Phase 2b Study and Association Between Patient-Reported Outcomes and Disease Activity
Laure Gossec¹, Philip Mease², Alice Gottlieb³, Deepak Assudani⁴, Jason Coarse⁵, Barbara Ink⁶ and Laura Coates⁷, ¹Sorbonne Université and Hôpital Universitaire Pitié Salpêtrière, Paris, France, ²Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ³Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, ⁴UCB Pharma, Slough, United Kingdom, ⁵UCB Pharma, Raleigh, NC, ⁶UCB Pharma, Slough, ⁷University of Oxford, Oxford, United Kingdom
Background/Purpose: Bimekizumab (BKZ), a humanized monoclonal IgG1 antibody that selectively neutralizes interleukin (IL)-17A and IL-17F, has shown clinical improvements in joint and skin outcomes and…
Abstract Number: 0990 • ACR Convergence 2020
Interferon Lambda Promotes Human Plasma Cell Differentiation in Lupus and Healthy Donors
Jennifer Barnas¹, Jennifer Albrecht¹ and Jennifer Anolik¹, ¹University of Rochester Medical Center, Rochester, NY
Background/Purpose: Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease characterized by antinuclear autoantibodies produced by plasma cells. Type I interferon (IFN) are cytokines which…
Abstract Number: 1368 • ACR Convergence 2020
Proportions of Patients Achieving a Minimal Disease Activity State upon Treatment with Tildrakizumab in a Psoriatic Arthritis Phase 2b Study
Peter Nash¹, Michael Luggen², Ferran J. García Fructuoso³, Richard Chou⁴, Alan Mendelsohn⁵, Stephen Rozzo⁵ and Iain McInnes⁶, ¹School of Medicine Griffith University, Brisbane, Queensland, Australia, ²University Hospital/University of Cincinnati College of Medicine, Cincinnati Rheumatic Disease Study Group, Inc, Cincinnati, OH, ³Hospital CIMA Sanitas, Barcelona, Spain, ⁴University at Buffalo, School of Medicine and Biomedical Sciences, Amherst, NY, ⁵Sun Pharmaceutical Industries, Inc., Princeton, NJ, ⁶Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Tildrakizumab (TIL) is a high-affinity anti–interleukin-23p19 monoclonal antibody approved in the US, EU, and Australia to treat moderate to severe plaque psoriasis.1 A randomized,…
Abstract Number: 0361 • ACR Convergence 2020
Response to Treatment with Ixekizumab in Patients with Active Non-Radiographic Axial Spondyloarthritis Based on HLA-B27 Status and Disease Duration
Victoria Navarro-Compán¹, Jose Maldonado-Cocco², Proton Rahman³, Andris Kronbergs⁴, David Sandoval⁴, So Young Park⁴, Theresa Hunter⁴ and Marina Magrey⁵, ¹Hospital Universitario La Paz IdiPaz, Madrid, Pais Vasco, Spain, ²University of Buenos Aires School of Medicine, Buenos Aires, Argentina, ³Memorial University of Newfoundland, Department of Medicine, St John's, Canada, ⁴Eli Lilly and Company, Indianapolis, ⁵Case Western Reserve University School of Medicine, Cleveland, OH
Background/Purpose: In this analysis, we evaluate the efficacy of ixekizumab at week 16 in patients with non-radiographic axial spondyloarthritis (nr-axSpA) with or without baseline HLA-B27…
Abstract Number: 0994 • ACR Convergence 2020
Does Tofacitinib Impact B Cell Functions?
Guillaume Decarriere¹, Julie Mielle², Bernard Combe³, Jacques Morel¹, Rachel Audo² and Claire Daien¹, ¹Rheumatology department, CHU Montpellier and University of Montpellier, Montpellier, France, ²Institut de génétique moléculaire de Montpellier (IGMM), Montpellier, France, ³University of Montpellier, Montpellier, France
Background/Purpose: Tofacitinib (tofa) inhibits cytokine signaling mediated by JAK1 JAK3 pathways leading therefore to a decrease in Th17 and an increase of Treg cells. The…
Abstract Number: 1369 • ACR Convergence 2020
Efficacy of Tildrakizumab in PsA: DAPSA Remission and Low Disease Activity in PASDAS Through Week 52
Saima Chohan¹, Arthur Kavanaugh², Vibeke Strand³, Richard Chou⁴, Alan Mendelsohn⁵, Stephen Rozzo⁵ and Philip Mease⁶, ¹Arizona Arthritis and Rheumatology Research, PLLC, Pheonix, AZ, ²UC San Diego Health System, San Diego, CA, ³Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, ⁴University at Buffalo, School of Medicine and Biomedical Sciences, Amherst, NY, ⁵Sun Pharmaceutical Industries, Inc., Princeton, NJ, ⁶Seattle Rheumatology Associates, P.L.L.C., Seattle, WA
Background/Purpose: Tildrakizumab (TIL), an anti–interleukin-23p19 monoclonal antibody, is approved in the US, EU, and Australia for treatment of moderate to severe plaque psoriasis. A randomized,…
Abstract Number: 0364 • ACR Convergence 2020
Subcutaneous Secukinumab 150 Mg Provides Sustained Relief in Total and Nocturnal Back Pain, Morning Stiffness, Fatigue, and Low Disease Activity in Patients with Active Ankylosing Spondylitis: End-of-study (5-year) Data from the MEASURE 2 Trial
Helena Marzo-Ortega¹, Corinne Miceli-Richard², Sonja Gill³, Marina Magrey⁴, Paula Machado⁵, Abhijit Shete⁶, Jianyuan Wang⁶, Susanne Rohrer⁶ and Atul Deodhar⁷, ¹The University of Leeds, Leeds Institute for Rheumatic and Musculoskeletal Medicine, NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust, Leeds, UK, Leeds, United Kingdom, ²Paris Descartes University, Department of Rheumatology - Hôpital Cochin, Assistance Publique - Hôpitaux de Paris, Paris, France, ³412 – 3075 Hospital Gate, Oakville, Canada, ⁴Case Western Reserve University School of Medicine, Cleveland, OH, ⁵Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁶Novartis Pharma AG, Basel, Switzerland, ⁷Oregon Health & Science University, Portland, OR
Background/Purpose: Patients (pts) with ankylosing spondylitis (AS) report pain (70–80%), stiffness (20–40%), and fatigue (50–60%) as the most troubling symptoms. Early diagnosis and sustained improvement…
Abstract Number: 1151 • ACR Convergence 2020
Implementation and Initial Experience with a Screening Protocol for Inflammatory Hyperferritinemia
Michael Zhang¹, Corinne Schneider², Vinh Dang² and Scott Canna³, ¹Children's Hospital UPMC, Pittsburgh, PA, ²University of Pittsburgh, Pittsburgh, ³University of PIttsburgh, Pittsburgh, PA
Background/Purpose: Macrophage activation syndrome (MAS) and hemophagocytic lymphohistiocytosis (HLH) epitomize a diverse and deadly group of inflammatory hyperferritinemic syndromes. Early biomarkers distinguishing these syndromes, especially…
Abstract Number: 1373 • ACR Convergence 2020
IL-23 Skin and Joint Profiling in Psoriatic Arthritis: Novel Perspectives in Understanding Clinical Responses to IL-23 Inhibitors
Alessandra Nerviani¹, Marie-Astrid Boutet¹, Wang Sin Gina Tan¹, Katriona Goldmann¹, Nirupam Purkayastha¹, Tamas Lajtos¹, Rebecca Hands¹, Myles Lewis¹, Stephen Kelly² and Costantino Pitzalis³, ¹Centre for Experimental Medicine and Rheumatology, Queen Mary University of London, London, United Kingdom, ²Mile End Hospital, Barts Health NHS Trust, London, United Kingdom, ³Queen Mary University of London, London, United Kingdom
Background/Purpose: PsA is a chronic heterogeneous inflammatory condition affecting up to 30% of patients with skin and/or nail psoriasis and the IL-23/IL-17 axis is believed…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].